: Over the last thirty years many noteworthy advances in the early detection of breast, colon, and prostate cancer have improved treatment and, in some instances, improved outcomes. Yet during this timeframe, the incidence of cancer continued to increase, morbidity from treatments (i.e., surgery, radiation and chemotherapy) remained unacceptable, and survival only improved marginally. The subject of this proposal is the application of a novel paramagnetic site-targeted contrast """"""""platform technology"""""""" for sensitive and specific imaging of molecular epitopes expressed on tumor neovasculature alone and in combination with the local delivery of chemotherapeutic agents to these sites. av?3-integrin nanoparticles effectively target solid animal tumors and human xenografts to provide marked MR T1-weighted contrast and potent anti-tumor therapy. Unfortunately, no single vascular biosignature is ubiquitous across all solid tumors. Therefore, tumors must be noninvasively interrogated against a broader panel of targeted agents in order to individualize therapy with the appropriate single or combination of ligand directed nanoparticles. This program, we will expand utility of this successful nanotechnology platform to additional early biosignatures that may be targeted alone or simultaneously for the most effective diagnostic and chemotherapeutic response. In parallel, we will develop noninvasive imaging software and hardware to exploit the unique opportunity presented by perfluorocarbon nanoparticles for 19F MR spectroscopy, 19F imaging, and 1H/19F hybrid imaging. The use of 19F spectroscopy and imaging will not only add quantitative and spectral dimensionality to targeted nanoparticle applications, but 19F imaging can also eliminate the need for baseline digital subtraction of images, which is time-consuming and prone to error. Interleaved 1H/19F hybrid imaging will minimize motion artifacts, eliminate image registration issues, confirm contrast identification and shorten patient scanning times.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S (O1))
Program Officer
Grodzinski, Piotr
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Pan, Dipanjan; Kim, Benjamin; Hu, Grace et al. (2015) A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy. Nanomedicine (Lond) 10:241-51
Goette, Matthew J; Keupp, Jochen; Rahmer, J├╝rgen et al. (2015) Balanced UTE-SSFP for 19F MR imaging of complex spectra. Magn Reson Med 74:537-43
Schmieder, Anne H; Caruthers, Shelton D; Keupp, Jochen et al. (2015) Recent Advances in (19)Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions. Engineering (Beijing) 1:475-489
Schmieder, Anne H; Winter, Patrick M; Williams, Todd A et al. (2013) Molecular MR imaging of neovascular progression in the Vx2 tumor with ?v?3-targeted paramagnetic nanoparticles. Radiology 268:470-80
Pan, Hua; Myerson, Jacob W; Hu, Lingzhi et al. (2013) Programmable nanoparticle functionalization for in vivo targeting. FASEB J 27:255-64
Wu, Lina; Luderer, Micah; Yang, Xiaoxia et al. (2013) Surface passivation of carbon nanoparticles with branched macromolecules influences near infrared bioimaging. Theranostics 3:677-86
Wu, Lina; Cai, Xin; Nelson, Kate et al. (2013) A Green Synthesis of Carbon Nanoparticle from Honey for Real-Time Photoacoustic Imaging. Nano Res 6:312-325
Hu, Lingzhi; Chen, Junjie; Yang, Xiaoxia et al. (2013) Rapid quantification of oxygen tension in blood flow with a fluorine nanoparticle reporter and a novel blood flow-enhanced-saturation-recovery sequence. Magn Reson Med 70:176-83
Hou, Kirk K; Pan, Hua; Lanza, Gregory M et al. (2013) Melittin derived peptides for nanoparticle based siRNA transfection. Biomaterials 34:3110-9
Hood, Joshua L; Jallouk, Andrew P; Campbell, Nancy et al. (2013) Cytolytic nanoparticles attenuate HIV-1 infectivity. Antivir Ther 18:95-103

Showing the most recent 10 out of 90 publications